Author:
Calle Rubio Myriam,López-Campos José Luis,Miravitlles Marc,Michel de la Rosa Francisco Javier,Hernández Pérez José María,Montero Martínez Carmen,Montoro Ronsano José Bruno,Casas Maldonado Francisco,Rodríguez Hermosa Juan Luis,Tabernero Huguet Eva María,Martínez Sesmero José Manuel,Martínez Rivera Carlos,Callejas González Francisco Javier,Torres Durán María
Abstract
Abstract
Background
Patients with alpha-1 antitrypsin deficiency (AATD), commonly categorized as a rare disease, have been affected by the changes in healthcare management brought about by COVID-19. This study’s aim was to identify the changes that have taken place in AATD patient care as a result of the COVID-19 pandemic in Spain and to propose experts’ recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation.
Methods
A qualitative descriptive case study with a holistic single-case design was conducted, using focus groups with experts in AATD clinical management, including 15 health professionals with ties to the Spanish health system (12 pneumologists and 2 hospital pharmacists from 11 different hospitals in Spain) and 1 patient representative.
Results
COVID-19 has had a major impact on numerous aspects of AATD clinical patient management in Spain, including diagnostic, treatment, and follow-up phases. The experts concluded that there is a need to strengthen coordination between Primary Care and Hospital Care and improve the coordination processes across all the organizations and actors involved in the healthcare system. Regarding telemedicine and telecare, experts have concluded that it is necessary to promote this methodology and to develop protocols and training programs. Experts have recommended developing personalized and precision medicine, and patient participation in decision-making, promoting self-care and patient autonomy to optimize their healthcare and improve their quality of life. The possibility of monitoring and treating AATD patients from home has also been proposed by experts. Another result of the study was the recommendation of the need to ensure that plasma donations are made on a regular basis by a sufficient number of healthy individuals.
Conclusion
The study advances knowledge by highlighting the challenges faced by health professionals and changes in AATD patient management in the context of the COVID-19 pandemic. It also proposes experts’ recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation. This work could serve as a reference study for physicians on their daily clinical practice with AATD patients and may also provide guidance on the changes to be put in place for the post-pandemic situation.
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Chiesa V, Antony G, Wismar M, Rechel B. COVID-19 pandemic: health impact of staying at home, social distancing and “lockdown” measures-a systematic review of systematic reviews. J Public Health (Oxf). 2021;43(3):e462–81.
2. Chowdhury SF, Al Sium SM, Anwar S. Research and management of rare diseases in the COVID-19 pandemic era: challenges and countermeasures. Front public Heal. 2021;9:640282.
3. Lampe C, Dionisi-Vici C, Bellettato CM, Paneghetti L, LingenBond CvanS, et al. The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys. Orphanet journal of rare diseases. 2020;15(1):341.
4. Talarico R, Aguilera S, Alexander T, Amoura Z, Antunes AM, Arnaud L, et al. The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. Nat Rev Rheumatol. 2021;17(3):177–84.
5. Sandhaus RA, Turino G, Brantly ML, Campos M, Cross CE, Goodman K, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis (Miami, Fla). 2016;3(3):668–82.